FDA Drug Approval Process Under Scrutiny: Leadership Intervention Raises Concerns Washington – A recent shift in the Food and Drug Administration’s (FDA) process for reviewing drugs granted Commissioner’s National Priority Vouchers is sparking debate and raising questions about potential political influence. The FDA had pledged expedited reviews – typically one to two months – for … Read more
Washington, D.C. – The biotechnology landscape shifted today with a series of significant developments, including the release of a new tranche of priority review vouchers by the Food and Drug Administration and reports of a serious adverse event in a groundbreaking CRISPR clinical trial. These events, coupled with Mark Cuban’s latest venture into the biosimilar … Read more
This is the online version of a report on healthcare financial updates. A significant shift in Medicare payment policies is poised to reshape the financial landscape for physicians in 2026. Late Friday, the Centers for Medicare & Medicaid Services (CMS) finalized its decision to implement a 2.5% reduction in payments for a wide range of … Read more
A staggering $8.6 billion. That’s the projected market size for treatments targeting transthyretin amyloid cardiomyopathy (ATTR-CM) by 2030, according to recent analysis. Alnylam Pharmaceuticals is not just participating in this growth; it’s rapidly becoming a dominant force, and its recent Q3 2025 earnings report confirms a trajectory that could redefine the landscape of genetic medicine. … Read more
FDA Moves to Accelerate Biosimilar Approvals, Potentially Lowering Drug Costs WASHINGTON – In a significant move aimed at increasing access to affordable medications, the Trump administration unveiled a draft framework Wednesday designed to expedite the approval process for biosimilar drugs. These “copycat” versions of complex biologic medications hold the promise of substantially reducing healthcare costs … Read more
Budigalimab Shows Promise in Delaying HIV Viral Rebound During Treatment Interruption In a significant development for HIV research, a new study indicates that the experimental drug budigalimab may offer a novel approach to controlling the virus. Early trial results reveal that budigalimab, a PD-1 inhibitor, was well-tolerated by participants and demonstrated the ability to delay … Read more